Clinical Trial Update: Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

This document updates on a Phase 1/2 clinical trial assessing different doses of BI-1607 in combination with pembrolizumab and ipilimumab for unresectable or me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Uveal Melanoma

Drugs mentioned

• BI-1607
• Pembrolizumab (pembrolizumab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: BioInvent International AB | Conditions: Melanoma Metastatic, Melanoma of Skin | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING